Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience

[1]  D. Schadendorf,et al.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[3]  J. Kupryjańczyk,et al.  MC13-0045 Genes from the TP53 network and their role in ovarian cancer prognosis and response to chemotherapy , 2013 .

[4]  J. Wolchok,et al.  Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.

[5]  J. Wolchok,et al.  Annals of the New York Academy of Sciences Development of Ipilimumab: a Novel Immunotherapeutic Approach for the Treatment of Advanced Melanoma , 2022 .

[6]  F. Hodi,et al.  Ipilimumab and its toxicities: a multidisciplinary approach. , 2013, The oncologist.

[7]  A. Tarhini.  Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management , 2013, Scientifica.

[8]  C. Berking,et al.  The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network , 2013, PloS one.

[9]  A. Hauschild,et al.  Management of immune-related adverse events and kinetics of response with ipilimumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Garber.  Anti-IL-17 mAbs herald new options in psoriasis , 2012, Nature Biotechnology.

[11]  S. Steinberg,et al.  Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[12]  I. Lowy,et al.  Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[13]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[14]  C. Mateus,et al.  Hemophilia A induced by ipilimumab. , 2011, The New England journal of medicine.

[15]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[16]  B. Neyns,et al.  Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  L. Min,et al.  Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. , 2011, European journal of endocrinology.

[18]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[19]  Jian Zhang,et al.  Cutting Edge: CTLA-4–B7 Interaction Suppresses Th17 Cell Differentiation , 2010, The Journal of Immunology.

[20]  H. Pehamberger,et al.  Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  D. Schadendorf,et al.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.

[22]  S. Targan,et al.  Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. , 2010, Cancer immunity.

[23]  A. Ribas,et al.  CTLA4 blockade increases Th17 cells in patients with metastatic melanoma , 2009, Journal of Translational Medicine.

[24]  Lisa M. Ebert,et al.  Melan-A–specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4 , 2009, Clinical Cancer Research.

[25]  M. Upton,et al.  Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. , 2009, Journal of immunotherapy.

[26]  G. Bottazzo,et al.  Anti-CTLA4 Antibody-Induced Lupus Nephritis , 2009 .

[27]  C. Yedinak,et al.  Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes , 2009, Pituitary.

[28]  J. Wolchok,et al.  CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit , 2008, Proceedings of the National Academy of Sciences.

[29]  N. Shastri,et al.  SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade , 2008, Proceedings of the National Academy of Sciences.

[30]  M. Gordon.  Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4 , 2008 .

[31]  P. Sharma,et al.  Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. , 2008, Cancer immunity.

[32]  S. Quezada,et al.  CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. , 2006, The Journal of clinical investigation.

[33]  A. Feldman,et al.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Rosenberg,et al.  Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. , 2006, Archives of dermatology.

[35]  S. Groshen,et al.  Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Rosenberg,et al.  Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. , 2005, Journal of immunotherapy.

[37]  S. Rosenberg,et al.  Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. , 2004, Journal of immunotherapy.

[38]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Thomas Davis,et al.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[41]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[42]  C. Thompson,et al.  Expression and function of CTLA-4 in Th1 and Th2 cells. , 1998, Journal of immunology.

[43]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[44]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.